Oxidative dna damage of lymphocytes in peripheral blood and ascites in cancer patients

Current Oncology

Volumn 19, Issue S1, 2012, Pages 10-14

  Wang, J ^a   Xing, S S ^b   Guo, Shi Biao ^a   Jin, W ^a   Zhang, Wei ^c  

^a YIDU CENTRAL HOSPITAL OF WEIFANG   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

DNA damage; Malignant ascites; total antioxidant capacity; tumour associated lymphocytes

Indexed keywords

EID: 84891291538     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1136     Document Type: Article

References (21)

1. Barni S, Cabiddu M, Ghilardi M, Petrelli F. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol 2011;79:144–53.
2. Chung M, Kozuch P. Treatment of malignant ascites. Curr Treat Options Oncol 2008;9:215–33.
3. Ziech D, Franco R, Pappa A, Panayiotidis MI. Reactive oxygen species (ros)–induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res 2011;711:167–73.
4. Ozenci V, Miller AM, Palmborg A, et al. Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer. Prostate 2005;65:20–6.
5. Labidi–Galy SI, Sisirak V, Meeus P, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011;71:5423–34.
6. Matsuzaki J, Gnjatic S, Mhawech–Fauceglia P, et al. Tumorinfiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107:7875–80.
7. Duluc D, Corvaisier M, Blanchard S, et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human t umor-associated macrophages. Int J Cancer 2009;125:367–73.
8. Webb TJ, Giuntoli RL 2nd, Rogers O, Schneck J, Oelke M. Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. Clin Cancer Res 2008;14:7652–8.
9. Mougiakakos D, Johansson CC, Kiessling R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 2009;113:3542–5.
10. Ghiselli A, Serafini M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med 2000;29:1106–14.
11. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925–6.
12. Mantovani G, Macciò A, Pisano M, et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous pbmcs but are capable of releasing high amounts of various cytokines. Int J Cancer 1997;71:724–31.
13. Benzie IF, Strain JJ. The ferric reducing ability of plasma (frap) as a measure of “antioxidant power”: the frap assay. Anal Biochem 1996;239:70–6.
14. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of dna damage in individual cells. Exp Cell Res 1988;175:184–91.
15. Everett SM, White KL, Schorah CJ, et al. In vivo dna damage in gastric epithelial cells. Mutat Res 2000;468:73–85.
16. Floyd RA, Towner RA, He T, Hensley K, Maples KR. Translational research involving oxidative stress and diseases of aging. Free Radic Biol Med 2011;51:931–41.
17. Montero AJ, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011;71:1385–96.
18. Wang D, Feng JF, Zeng P, Yang YH, Luo J, Yang YW. Total oxidant/antioxidant status in sera of patients with thyroid cancers. Endocr Relat Cancer 2011;18:773–82.
19. Xing M. Oxidative stress: a new risk factor for thyroid cancer. Endocr Relat Cancer 2012;19:C7–11.
20. Somogyi A, Rosta K, Pusztai P, Tulassay Z, Nagy G. Antioxidant measurements. Physiol Meas 2007;28:R41–55.
21. Liu X, Zhao J, Zheng R. dna damage of tumor-associated lymphocytes and total antioxidant capacity in cancerous patients. Mutat Res 2003;539:1–8.